tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
ServiceTitan initiated, Viracta downgraded: Wall Street’s top analyst calls
PremiumThe FlyServiceTitan initiated, Viracta downgraded: Wall Street’s top analyst calls
7M ago
Viracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
Premium
The Fly
Viracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
7M ago
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
Premium
Company Announcements
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
7M ago
Viracta Therapeutics reports 42% reduction in force, strategic reprioritization
PremiumThe FlyViracta Therapeutics reports 42% reduction in force, strategic reprioritization
9M ago
Viracta Therapeutics Restructures to Focus on Nana-val Program
Premium
Company Announcements
Viracta Therapeutics Restructures to Focus on Nana-val Program
9M ago
VIRX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
VIRX Upcoming Earnings Report: What to Expect?
9M ago
Viracta Therapeutics reports Q2 EPS (25c) vs (32c) lastyear
PremiumThe FlyViracta Therapeutics reports Q2 EPS (25c) vs (32c) lastyear
12M ago
VIRX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
VIRX Upcoming Earnings Report: What to Expect?
12M ago
Xoma receives $8.1M milestone related to Day One’s sale of PRV
Premium
The Fly
Xoma receives $8.1M milestone related to Day One’s sale of PRV
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100